At the Nanjing Xin100 Annual General Meeting of Shareholders, Chairman Zhai Lingyun said that the Singaporean listed company Cordlife (Cordlife), in which the company is a shareholder, had some problems in early operation, mainly due to insufficient professionalism and business ability of the local management team. Kangsheng Life re-elected its board of directors this month, and the company strengthened its influence and voice. After that, it is planned to enhance Kangsheng Life's management capabilities through management and technology export, resolve the company's technical risks and adverse social impacts, and resume normal operations as soon as possible. I believe Kangsheng Life still has great potential for development in the future. Small note: Earlier this year, Kangsheng Life was involved in a scandal of cord blood storage problems. Afterwards, the Ministry of Health of Singapore requested the company to suspend operations. (CIFA reporter Wu Chao)